康希诺生物盘中涨超15%,截至发稿,股价上涨11.93%,现报36.60港元,成交额8471.12万港元。5月15日,康希诺生物发布公告,公司已获得印度尼西亚食品药品监督管理局颁发的I期临床试验批准,可以启动公司开发的吸入用肺结核疫苗(5型腺病毒载体)(吸入用结核病加强疫苗)的相关临床试验。湘财证券指出,康希诺生物一季度业绩超预期,归母净亏损大幅收窄得益于曼海欣的积极表现和降本增效。该行指出,已...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.